Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -11538.23% is 901% below its 3-year average of -1152.56%, around the middle of its 3-year range (-18638.71%–74.51%).
119.53% below its 12-month average of -5255.81%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2023 (2023-06-30): -18638.71%.
EBITDA MARGIN
-11538.23%
EBITDA MARGIN AVG TTM
-5255.81%
EBITDA MARGIN AVG 3Y
-1354.12%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-119.53%
CURRENT VS 3Y AVG
-752.08%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pliant Therapeutics, Inc.
Market Cap
$63.78M
EBITDA Margin
-11538.23%
TTM Avg
-5255.81%
3Y Avg
-1354.12%
5Y Avg
N/A
Market Cap
$64.18M
EBITDA Margin
-46.36%
TTM Avg
-44.45%
3Y Avg
-49.00%
5Y Avg
-37.18%
Market Cap
$62.78M
EBITDA Margin
-0.14%
TTM Avg
-3.20%
3Y Avg
-62.68%
5Y Avg
-125.61%
Market Cap
$62.62M
EBITDA Margin
-1113.80%
TTM Avg
-13312.72%
3Y Avg
-13312.72%
5Y Avg
-13312.72%
Market Cap
$65.85M
EBITDA Margin
-794.91%
TTM Avg
-458.44%
3Y Avg
-317.77%
5Y Avg
-317.77%
Market Cap
$65.87M
EBITDA Margin
-334.74%
TTM Avg
-191.68%
3Y Avg
-191.68%
5Y Avg
-191.68%
Market Cap
$60.42M
EBITDA Margin
-99843.01%
TTM Avg
-70984.01%
3Y Avg
-70984.01%
5Y Avg
-70984.01%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | $63.78M | -11538.23% | -5255.81% | -1354.12% | N/A |
| Alps Group Inc (ALPS)vs › | $64.18M | -46.36% | -44.45% | -49.00% | -37.18% |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.84% | -6.43% | -1.20% | -7.11% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -0.14% | -3.20% | -62.68% | -125.61% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | -1113.80% | -13312.72% | -13312.72% | -13312.72% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -794.91% | -458.44% | -317.77% | -317.77% |
| Cingulate Inc. (CING)vs › | $65.86M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -334.74% | -191.68% | -191.68% | -191.68% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
| iBio, Inc. (IBIO)vs › | $67.52M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
Gross Margin
0.0%
EBITDA Margin
-11538.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-06-30 | -18638.71% |
| 2023-03-31 | -3080.63% |
| 2022-12-31 | -1849.72% |
| 2022-09-30 | -2125.03% |
| 2022-06-30 | -584.95% |
| 2022-03-31 | -2222.26% |
| 2021-12-31 | -1209.65% |
| 2021-09-30 | -1659.94% |
| 2021-06-30 | -1259.59% |
| 2021-03-31 | -1037.72% |
| 2020-12-31 | -418.12% |
| 2020-09-30 | -339.24% |
| 2020-06-30 | -462.64% |
| 2020-03-31 | 39.12% |
| 2019-12-31 | 74.51% |
